X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3546) 3546
sulfonylurea compounds - therapeutic use (2841) 2841
diabetes mellitus, type 2 - drug therapy (2202) 2202
hypoglycemic agents - therapeutic use (2118) 2118
male (1997) 1997
female (1911) 1911
middle aged (1684) 1684
aged (1350) 1350
endocrinology & metabolism (1106) 1106
adult (986) 986
type 2 diabetes (960) 960
insulin - therapeutic use (918) 918
metformin - therapeutic use (905) 905
diabetes (842) 842
diabetes mellitus, type 2 - blood (769) 769
drug therapy, combination (724) 724
diabetes mellitus - drug therapy (719) 719
insulin (699) 699
sulfonylurea compounds - adverse effects (677) 677
hypoglycemic agents - adverse effects (650) 650
metformin (649) 649
blood glucose - metabolism (627) 627
hypoglycemic agents - administration & dosage (542) 542
sulfonylurea compounds - administration & dosage (526) 526
treatment outcome (503) 503
animals (455) 455
sulfonylurea (448) 448
glucose (438) 438
pharmacology & pharmacy (435) 435
mellitus (407) 407
diabetes mellitus (404) 404
thiazolidinediones - therapeutic use (403) 403
medicine, general & internal (396) 396
glycemic control (395) 395
diabetes mellitus, type 2 - complications (376) 376
sulfonylurea compounds - pharmacology (375) 375
glycated hemoglobin a - metabolism (368) 368
administration, oral (365) 365
risk factors (365) 365
blood glucose - analysis (359) 359
hypoglycemic agents (350) 350
care and treatment (336) 336
hypoglycemia - chemically induced (333) 333
drug therapy (330) 330
hypoglycemic agents - pharmacology (328) 328
blood glucose - drug effects (321) 321
hypoglycemia (315) 315
glimepiride (313) 313
time factors (302) 302
sulfonylurea compounds (299) 299
glycated hemoglobin a - analysis (297) 297
diabetes therapy (295) 295
insulin - blood (294) 294
risk (291) 291
therapy (286) 286
glyburide - therapeutic use (271) 271
sulfonylureas (270) 270
insulin - metabolism (269) 269
internal medicine (267) 267
dipeptidyl-peptidase iv inhibitors - therapeutic use (259) 259
research (259) 259
aged, 80 and over (256) 256
analysis (253) 253
insulin resistance (250) 250
mortality (250) 250
double-blind method (249) 249
retrospective studies (247) 247
diabetes mellitus, type 2 - metabolism (243) 243
diabetes mellitus, type 2 - physiopathology (241) 241
biguanides - therapeutic use (239) 239
hyperglycemia (237) 237
metformin - administration & dosage (234) 234
double-blind (233) 233
insulin secretion (230) 230
type 2 diabetes mellitus (229) 229
glibenclamide (227) 227
thiazolidinediones (220) 220
adolescent (199) 199
medicine & public health (197) 197
metformin - adverse effects (194) 194
health aspects (193) 193
cohort studies (184) 184
efficacy (182) 182
body mass index (181) 181
rats (181) 181
management (180) 180
clinical trials (176) 176
dextrose (173) 173
insulin - administration & dosage (173) 173
follow-up studies (167) 167
clinical trials as topic (166) 166
association (163) 163
hypoglycemic sulfonylureas (160) 160
safety (160) 160
rosiglitazone (159) 159
dose-response relationship, drug (155) 155
pioglitazone (155) 155
dosage and administration (153) 153
type-2 diabetes-mellitus (152) 152
body weight (150) 150
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3450) 3450
German (175) 175
French (92) 92
Japanese (70) 70
Italian (46) 46
Russian (45) 45
Spanish (45) 45
Polish (33) 33
Chinese (17) 17
Portuguese (15) 15
Hungarian (11) 11
Czech (9) 9
Danish (9) 9
Dutch (6) 6
Swedish (6) 6
Finnish (4) 4
Bulgarian (3) 3
Croatian (3) 3
Hebrew (3) 3
Norwegian (3) 3
Ukrainian (3) 3
Serbian (2) 2
Korean (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2012, Volume 380, Issue 9840, pp. 475 - 483
Summary Background Addition of a sulphonylurea to metformin improves glycaemic control in type 2 diabetes, but is associated with hypoglycaemia and weight... 
Internal Medicine | ALL-CAUSE MORTALITY | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | ADD-ON | METAANALYSIS | SULFONYLUREA | GLUCOSE CONTROL | CARDIOVASCULAR-DISEASE | RISK | COMPLICATIONS | MELLITUS | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Purines - administration & dosage | Hypoglycemic Agents - administration & dosage | Treatment Failure | Adult | Female | Quinazolines - administration & dosage | Linagliptin | Purines - adverse effects | Purines - therapeutic use | Sulfonylurea Compounds - administration & dosage | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Sulfonylurea Compounds - therapeutic use | Treatment Outcome | Sulfonylurea Compounds - adverse effects | Diabetes Mellitus, Type 2 - blood | Quinazolines - therapeutic use | Quinazolines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Research Design | Type 2 diabetes | Complications and side effects | Dosage and administration | Metformin | Drug therapy | Hypoglycemic sulfonylureas | Sulfonylurea compounds | Glimepiride | Comparative analysis | Heart attacks | Diabetes | Pharmaceutical industry | Drug dosages | Drugs | Obesity | Body weight | Diabetes mellitus
Journal Article
European heart journal, ISSN 1522-9645, 2015, Volume 36, Issue 34, pp. 2288 - 2296
Journal Article
Nature reviews. Endocrinology, ISSN 1759-5037, 2016, Volume 12, Issue 10, pp. 566 - 592
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 2011, Volume 2011, Issue 9, p. CD006165
Background Latent autoimmune diabetes in adults (LADA) is a slowly developing type 1 diabetes. Objectives To compare interventions used for LADA. Search... 
Endocrine & metabolic | Drugs, Chinese Herbal | Other types of diabetes | Diabetes mellitus | Glutamate Decarboxylase | Insulin | Randomized Controlled Trials as Topic | Other types of Diabetes mellitus | Hypoglycemic Agents | Autoimmune Diseases | Glycated Hemoglobin A | Diabetes Mellitus, Type 2 | Diabetes mellitus and Related Disorders | Metformin | Sulfonylurea Compounds | Diabetes | Medicine General & Introductory Medical Sciences | Thiazolidinediones | Latent autoimmune diabetes in adults (LADA) | Type 1 [drug therapy | Glutamate Decarboxylase [therapeutic use] | Humans | FOLLOW-UP | Autoimmune Diseases [ drug therapy | SUBCUTANEOUS INSULIN | ORAL INSULIN | MEDICINE, GENERAL & INTERNAL | C-Peptide [blood] | GAD AUTOANTIBODIES | Islets of Langerhans [immunology] | Adult | Hemoglobin A, Glycosylated [metabolism] | immunology | Thiazolidinediones [therapeutic use] | YOUNG-ADULTS | GLUTAMIC-ACID DECARBOXYLASE | ISLET-CELL | Insulin [therapeutic use] | Drugs, Chinese Herbal [therapeutic use] | Diabetes Mellitus | METABOLIC-CONTROL | BETA-CELL FUNCTION | Hypoglycemic Agents [therapeutic use] | Type 2 [drug therapy | DOUBLE-BLIND | Sulfonylurea Compounds [therapeutic use] | Hypoglycemic Agents - therapeutic use | Metformin - therapeutic use | Glycated Hemoglobin A - metabolism | Sulfonylurea Compounds - therapeutic use | Autoimmune Diseases - immunology | Thiazolidinediones - therapeutic use | Diabetes Mellitus, Type 2 - immunology | Glutamate Decarboxylase - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drugs, Chinese Herbal - therapeutic use | Autoimmune Diseases - drug therapy | Insulin - therapeutic use
Journal Article
Journal Article
Diabetologia, ISSN 1432-0428, 2009, Volume 52, Issue 10, pp. 2046 - 2055
Journal Article
Kidney international, ISSN 0085-2538, 02/2015, Volume 87, Issue 2, pp. 308 - 322
This review mainly focuses on metformin, and considers oral antidiabetic therapy in kidney transplant patients and the potential benefits and risks of... 
Type 2 diabetes | lactic acidosis | pharmacokinetics | metformin | chronic kidney disease | antidiabetic agents | ORGANIC CATION TRANSPORTER-1 | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | OXYGEN-CONSUMPTION | INDUCED HYPOGLYCEMIA | CLINICAL PHARMACOKINETICS | IN-VITRO DEGRADATION | UROLOGY & NEPHROLOGY | MITOCHONDRIAL DYSFUNCTION | LACTIC-ACIDOSIS | CHRONIC KIDNEY-DISEASE | TYPE-2 DIABETES-MELLITUS | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Diabetic Nephropathies - drug therapy | Glycoside Hydrolase Inhibitors - therapeutic use | Incretins - pharmacokinetics | Diabetes Mellitus, Type 2 - metabolism | Metformin - adverse effects | Thiazolidinediones - pharmacokinetics | Thiazolidinediones - therapeutic use | Glycoside Hydrolase Inhibitors - pharmacokinetics | Acidosis, Lactic - etiology | Renal Insufficiency - drug therapy | Sulfonylurea Compounds - pharmacokinetics | Hypoglycemic Agents - therapeutic use | Hypoglycemic Agents - pharmacokinetics | Metformin - pharmacokinetics | Diabetic Nephropathies - metabolism | Sulfonylurea Compounds - therapeutic use | Renal Insufficiency - metabolism | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Acidosis, Lactic - metabolism | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - pharmacokinetics | Insulin - therapeutic use | Kidney Transplantation - adverse effects
Journal Article